Bempegaldesleukin (NKTR-214) has been developed as a novel pegylated interleukin-2 (IL-2) cytokine prodrug that activates effector CD8+ T cells and NK cells within the tumor microenvironment [69,70,71]. This evidence concerns the gene CD8A and neoplasm.